15 completed, 8 terminated, 3 withdrawn, 2 unknown. 7 Phase 3, 7 Phase 4, 6 Phase 2, 4 Phase 1, 1 Not applicable.
Follow dalbavancin: new trials by email Literature Review of dalbavancin trials Research Report on dalbavancin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimised Dalbavancin Dosing for Serious Gram-Positive Bacterial Infections dalbavancin - Serious Gram-Positive Bacterial Infections | Not yet recruiting | Kirby Institute | 50 | 2027-01-01 | 2026-10-05 | |
| A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia Dalbavancin, Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician) - Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 29 | 2025-05-22 | 2026-09-15 |
| Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis Long-Acting silver dressings, Aloe Vera, Dalbavancin - Frostbite | Phase 4 | Unknown | University of Colorado, Denver | 100 | 2024-03-01 | 2024-05-13 |
| Comparing Oral Versus Parenteral Antimicrobial Therapy Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem - Endovascular Infection, Bone and Joint Infection | Phase 4 | Terminated | West Virginia University | 94 | 2023-08-04 | 2025-08-26 |
| Dalbavancin Outpatient Pilot Dalbavancin - Gram-Positive Bacterial Infections, Soft Tissue Infections | Phase 4 | Withdrawn | Wake Forest University Health Sciences | 2023-04-01 | 2023-05-03 | |
| Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements Dalbavancin - Osteoarticular Infection | Not applicable | Active not recruiting | Centre Hospitalier Universitaire de Nice | 43 | 2022-03-07 | 2026-06-22 |
| Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA) Dalbavancin - Diabetes, Infection | Completed | Aziende Chimiche Riunite Angelini Francesco S.p.A | 98 | 2022-01-02 | 2022-09-21 | |
| Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition Dalbavancin - Gram-Positive Bacterial Infections, Gram-Positive Bacteraemia | Phase 2 / Phase 3 | Terminated | University of Colorado, Denver | 11 | 2021-04-30 | 2023-10-19 |
| DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia Cefazolin, Dalbavancin, Daptomycin - Staphylococcal Bacteraemia | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2021-04-22 | 2024-12-10 |
| Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI Xydalba, vancomycin, teicoplanin or daptomycin - Acute Bacterial Skin and Skin Structure Infection | Completed | Aziende Chimiche Riunite Angelini Francesco S.p.A | 184 | 2020-06-18 | 2022-03-04 | |
| Evaluation of Intravenous Dalbavancin for Peritonitis Dalbavancin - Peritonitis, Peritonitis Bacterial | Terminated | University of Colorado, Denver | 2 | 2020-06-01 | 2024-05-09 | |
| Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections Dalbavancin Injection - Prosthesis-related Infections | Completed | Tourcoing Hospital | 15 | 2020-01-01 | 2023-10-18 | |
| Hospital Avoidance Strategies for ABSSSI Dalbavancin - Skin Infection | Phase 4 | Terminated | Washington University School of Medicine | 11 | 2019-03-04 | 2022-12-09 |
| Xydalba Utilization Registry in Germany Xydalba - Bacterial Infections | Terminated | Correvio International Sarl | 16 | 2018-11-21 | 2020-07-17 | |
| Xydalba Utilization Registry in France Xydalba - Bacterial Infections | Completed | Correvio International Sarl | 151 | 2018-09-06 | 2021-07-20 | |
| Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections Dalbavancin, Vancomycin - Bone Infection, Osteomyelitis | Phase 4 | Completed | Infectious Diseases Physicians, Inc. | 41 | 2018-01-25 | 2023-10-03 |
| Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Dalbavancin, Usual Care - Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection | Phase 4 | Completed | Allergan | 91 | 2017-07-24 | 2020-01-18 |
| Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Dalbavancin, Standard of Care - Osteomyelitis | Phase 2 | Terminated | Allergan | 1 | 2017-05-15 | 2018-09-26 |
| Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis Dalbavancin, Standard of Care - Endocarditis, Bacteremia | Phase 2 | Terminated | AbbVie | 2 | 2017-05-12 | 2022-04-25 |
| Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Dalbavancin, Vancomycin, Oxacillin - Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections | Phase 3 | Completed | AbbVie | 199 | 2017-03-30 | 2024-09-19 |
Showing 20 of 31. Sign in to see all of them.
Bacterial Infections (7) · Cellulitis (5) · Osteomyelitis (4) · Abscess (3) · Bacteremia (3) · Surgical Wound Infection (3) · Wound Infection (3) · Gram-Positive Bacterial Infections (2) · Patient Satisfaction (2) · Soft Tissue Infections (2) · Arthritis, Infectious (1) · Community-Acquired Pneumonia (1) · Diabetes Mellitus (1) · Emergencies (1) · Endocarditis (1)
Durata Therapeutics Inc., an affiliate of Allergan plc (6) · AbbVie (3) · Allergan (3) · University of Colorado, Denver (3) · Aziende Chimiche Riunite Angelini Francesco S.p.A (2) · Correvio International Sarl (2) · Centre Hospitalier Universitaire de Nice (1) · Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) (1) · Infectious Diseases Physicians, Inc. (1) · Kirby Institute (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Pfizer (1) · St. Jude Children's Research Hospital (1) · Tourcoing Hospital (1) · Vicuron Pharmaceuticals (1)
United States (21) · Ukraine (5) · Russia (4) · Bulgaria (3) · Estonia (3) · France (3) · Georgia (3) · Latvia (3) · Romania (3) · South Africa (3) · Canada (2) · Croatia (2) · Germany (2) · Greece (2) · Hungary (2)
Urania Rappo, MD (4) · Michael Dunne, MD (3) · Patrick Gillard (2) · Alena Jamdourek, MD (1) · Arek Wiktor, MD (1) · Arif R. Sarwari, MD, MSc, MBA (1) · Caryn Morse, MD (1) · Donald Poretz, MD (1) · Joshua Wolf, MBBS (1) · Joy J. Juskowich, MD (1) · Kiran Bhirangi, MBBS FRCS I (1) · Marianne Martinello, A Prof (1)
PMID 34905144, PMID 24897082, PMID 26611777, PMID 30648126, PMID 30797084, PMID 31713130, PMID 33780567, PMID 35578360, PMID 38211660, PMID 38249543, PMID 40802264, PMID 41419216, PMID 41999282
2014 (2), 5UM1AI104681-12 (1)